Jailan Elayoubi

Original ArticleArticles in PressOpen access Affiliations & Notes 1Karmanos Cancer Institute, Detroit, MI, USA 2Ataraxis AI, New York, NY, USA 3Mayo Clinic, Rochester, MN, USA 4Winship Cancer Institute of Emory University, Atlanta, GA, USA 5National Research Institute of Oncology in Warsaw, Warsaw, Poland 6Northwell Health, New York, NY, USA 7University of Arizona College of Medicine, Tucson, AZ, USA 8University of Colorado Anschutz Medical Campus, Aurora, CO, USA Article Info Publication...

Abstract Treatment selection in breast cancer is guided by risk assessment using molecular subtypes and clinicopathological characteristics. However, current approaches lack the precision required for optimal clinical decision-making. To address this, we use data from 8161 patients to develop and evaluate an AI test integrating digital pathology with clinical data. The AI test provides a robust method for predicting disease-free interval (C-index: 0.71 [0.68-0.75], HR: 3.63 [3.02-4.37, p < 0.001]).